Official Title
Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Brief Summary

With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells. Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation, homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients.

Withdrawn
COVID

Drug: Pentoxifylline

Pentoxifylline 400 mg SR tablet

Drug: Placebo

Placebo tablet

Eligibility Criteria

Inclusion Criteria:

- Positive COVID-19 test

- Age >/= 18 y.o.

Exclusion Criteria:

- Allergic reaction to Pentoxifylline

- Ongoing anticoagulation

- History of GI bleeding

- History of Seizures

- Cardiac or other vascular stents

- History of severe renal disease

- History of intracranial hemorrhage.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 60 Years
Countries
Egypt
Locations

Faculty of Medicine
Shibīn Al Kawm, Egypt

Sadat City University
NCT Number
MeSH Terms
Pentoxifylline